Pathology of inflammatory native valvular heart disease

Cardiovascular Pathology

Volumn 15, Issue 5, 2006, Pages 243-251

  Veinot, John P ^a  

^a Laboratory Medicine   (Canada)

Author keywords

Heart valve; Inflammation; Medication; Rheumatic fever

Indexed keywords

ANTIGENICITY; AORTA VALVE DISEASE; ARTICLE; BETA HEMOLYTIC STREPTOCOCCUS; CELLULAR IMMUNITY; ENDOCARDITIS; HIGH RISK PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; PATHOLOGY; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATIC FEVER; VALVULAR HEART DISEASE;

ANIMALS; HEART VALVE DISEASES; HUMANS; INFLAMMATION; RHEUMATIC HEART DISEASE;

EID: 33748418188     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2006.04.007     Document Type: Article

References (73)

1. Rullan E., and Sigal L.H. Rheumatic fever. Curr Rheumatol Rep 3 (2001) 445-452
2. World Health Organization. Diagnosis of rheumatic fever. In: World Health Organization (Ed). Rheumatic fever and rheumatic heart disease. Report of a WHO Expert Consultation, Geneva, 20 October-1 November 2001 (2004), World Health Organization, Geneva 20-40
3. Kadir S., Barker T.A., Clarke B., et al. Recurrent acute rheumatic fever: a forgotten diagnosis?. Ann Thorac Surg 78 (2004) 699-701
4. World Health Organization. Epidemiology of group A streptococci, rheumatic fever and rheumatic heart disease. In: World Health Organization (Ed). Rheumatic fever and rheumatic heart disease. Report of a WHO Expert Consultation, Geneva, 29 October-1 November 2001 (2004), World Health Organization, Geneva 13-19
5. Olivier C. Rheumatic fever-is it still a problem?. J Antimicrob Chemother 45 (2000) 13-21
6. Hilario M.O., and Terreri M.T. Rheumatic fever and post-streptococcal arthritis. Best Pract Res Clin Rheumatol 16 (2002) 481-494
7. Cunningham M.W. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front Biosci 8 (2003) s533-s545
8. Guilherme L., and Kalil J. Rheumatic fever: from sore throat to autoimmune heart lesions. Int Arch Allergy Immunol 134 (2004) 56-64
9. Cunningham M.W. T cell mimicry in inflammatory heart disease. Mol Immunol 40 (2004) 1121-1127
10. Stollerman G.H. Rheumatic fever in the 21st century. Clin Infect Dis 33 (2001) 806-814
11. Guilherme L., Cury P., Demarchi L.M.F., et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol 165 (2004) 1583-1591
12. Davutoglu V., Celik A., and Aksoy M. Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J Heart Valve Dis 14 (2005) 251-256
13. Roberto S., Kosanke S., Dunn S.T., et al. Pathogenic mechanisms in rheumatic carditis: focus on valvular endothelium. J Infect Dis 183 (2001) 507-511
14. Jian B., Xu J., Connolly J., et al. Serotonin mechanisms in heart valve disease: I. Serotonin-induced up-regulation of transforming growth factor-{beta}1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 161 (2002) 2111-2121
15. Gotlieb A.I., Rosenthal A., and Kazemian P. Fibroblast growth factor 2 regulation of mitral valve interstitial cell repair in vitro. J Thorac Cardiovasc Surg 124 (2002) 591-597
16. Durbin A.D., and Gotlieb A.I. Advances towards understanding heart valve response to injury. Cardiovasc Pathol 11 (2002) 69-77
17. Shworak N.W. Angiogenic modulators in valve development and disease: does valvular disease recapitulate developmental signaling pathways?. Curr Opin Cardiol 19 (2004) 140-146
18. Xu J., Jian B., Chu R., et al. Serotonin mechanisms in heart valve disease: II. The 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 161 (2002) 2209-2218
19. Walker G.A., Masters K.S., Shah D.N., et al. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 95 (2004) 253-260
20. Gustafsson B.I., Tommeras K., Nordrum I., et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 111 (2005) 1517-1522
21. Simula D.V., Edwards W.D., Tazelaar H.D., et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 77 (2002) 139-147
22. Thorson A.H. Studies on carcinoid disease. Acta Med Scand 161 (1958) 1-132
23. Rothman R.B., Baumann M.H., Savage J.E., et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 (2000) 2836-2841
24. Hauck A.J., Edwards W.D., Danielson G.K., et al. Mitral and aortic valve disease associated with ergotamine therapy for migraine. Arch Pathol Lab Med 114 (1990) 62-64
25. Redfield M.M., Nicholson W.J., Edwards WD., et al. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 117 (1992) 50-52
26. Fishman A.P. Aminorex to fen/phen: an epidemic foretold. Circulation 99 (1999) 156-161
27. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 (1997) 581-588
28. Sachdev M., Miller W.C., Ryan T., et al. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 144 (2002) 1065-1073
29. Kimmel S.E., Keane M.G., Crary J.L., et al. Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol 84 (1999) 304-308
30. Steffee C.H., Singh H.K., and Chitwood W.R. Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 8 (1999) 245-253
31. Volmar K.E., and Hutchins G.M. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 125 (2001) 1555-1561
32. McDonald P.C., Wilson J.E., Gao M., et al. Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion?. Cardiovasc Pathol 11 (2002) 251-262
33. Pritchett A.M., Morrison J.F., Edwards W.D., et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 (2002) 1280-1286
34. Hong Z.G., Smith A.J., Archer SL., et al. Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation 112 (2005) 1494-1499
35. Setola V., Hufeisen S.J., Grande-Allen K.J., et al. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63 (2003) 1223-1229
36. Mohler E.R. Mechanisms of aortic valve calcification. Am J Cardiol 94 (2004) 1396-1402
37. Rajamannan N.M., Subramaniam M., Rickard D., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107 (2003) 2181-2184
38. Wallby L., Janerot-Sjoberg B., Steffensen T., et al. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 88 (2002) 348-351
39. Mohler E.R., Gannon F., Reynolds C., et al. Bone formation and inflammation in cardiac valves. Circulation 103 (2001) 1522-1528
40. Wierzbicki A., and Shetty C. Aortic stenosis: an atherosclerotic disease?. J Heart Valve Dis 8 (1999) 416-423
41. Palta S., Pai A.M., Gill KS., et al. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 101 (2000) 2497-2502
42. Aronow W.S., Ahn C., Kronzon I., et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88 (2001) 693-695
43. Srivatsa S.S., Harrity P.J., Maercklein PB., et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest 99 (1997) 996-1009
44. Bostrom K., and Demer L.L. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryot Gene Expr 10 (2000) 151-158
45. Davies M.R., and Davies K.A. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 60 (2001) 472-479
46. Cimini M., Bougher D.R., Ronald JA., et al. Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study. J Heart Valve Dis 14 (2005) 365-375
47. Kaden J.J., Dempfle C.E., Grobholz R., et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 14 (2005) 80-87
48. Leask R.L., Jain N., and Butany J. Endothelium and valvular diseases of the heart. Microsc Res Tech 60 (2003) 129-137
49. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
50. McKenney J.M. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 96 (2005) 60E-66E
51. Farmer J.A., and Gotto A.M. The heart protection study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 92 (2003) 3i-9i
52. Ong H.T. Protecting the heart: a practical review of the statin studies. MedGenMed 4 (2002) 1
53. Tousoulis D., Davies G., Stefanadis C., et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 89 (2003) 993-997
54. Kullo I.J., Edwards W.D., and Schwartz R.S. Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 129 (1998) 1050-1060
55. Arnaud C., Braunersreuther V., and Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 15 (2005) 202-206
56. Rajamannan N.M., Subramaniam M., Caira F., et al. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112 (2005) I 229-I 234
57. Rajamannan N.M., Subramaniam M., Springett M., et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105 (2002) 2660-2665
58. Antonini-Canterin F., Popescu B.A., and Huang G. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment?. Ital Heart J 6 (2005) 119-124
59. Antonini-Canterin F., Zuppiroli A., Popescu BA., et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 92 (2003) 1479-1482
60. Shavelle D.M., Takasu J., Budoff MJ., et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359 (2002) 1125-1126
61. Cowell S.J., Newby D.E., Prescott RJ., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005) 2389-2397
62. Wu B., Elmariah S., Kaplan F.S., et al. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler Thromb Vasc Biol 25 (2005) 592-597
63. Maher E.R., Young G., Smyth-Walsh B., et al. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 2 (1987) 875-877
64. Straumann E., Meyer B., Misteli M., et al. Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J 67 (1992) 236-239
65. Braun J., Oldendorf M., Moshage W., et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27 (1996) 394-401
66. Malergue M.C., Urena P., Prieur P., et al. Incidence and development of aortic stenosis in chronic hemodialysis. An ultrasonographic and biological study of 112 patients. Arch Mal Coeur Vaiss 90 (1997) 1595-1601
67. Ribeiro S., Ramos A., Brandao A., et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 13 (1998) 2037-2040
68. Kajbaf S., Veinot J.P., Ha A., et al. Comparison of surgically removed cardiac valves of patients with ESRD with those of the general population. Am J Kidney Dis 46 (2005) 86-93
69. Blacher J., Guerin A.P., Pannier B., et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 (2001) 938-942
70. Zimmermann J., Herrlinger S., Pruy A., et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 (1999) 648-658
71. Tomaru T., Uchida Y., Mohri N., et al. Post inflammatory mitral and aortic valve prolapse: a clinical and pathological study. Circulation 76 (1987) 68-76
72. Tomaru T. The multifactorial etiology of mitral valve prolapse, a new entity of postinflammatory mitral valve prolapse. Herz 13 (1988) 271-276
73. Van der Bel-Kahn J., and Becker A.E. The surgical pathology of rheumatic and floppy mitral valves. Distinctive morphologic features upon gross examination. Am J Surg Pathol 10 (1986) 282-292